Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
about
Chronic kidney disease mineral and bone disorder in childrenFGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho)Fibroblast growth factor 23Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolismRegulation and function of the FGF23/klotho endocrine pathwaysBone disease in pediatric chronic kidney diseaseFibroblast Growth Factor 23: A New Dimension to Diseases of Calcium-Phosphorus MetabolismRole of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney diseaseFibrous dysplasia and fibroblast growth factor-23 regulationCalcium and phosphate impact cardiovascular risk.Biomarkers in chronic kidney disease, from kidney function to kidney damageHomozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient miceFGF23 fails to inhibit uremic parathyroid glandsIntravenous phosphate loading increases fibroblast growth factor 23 in uremic ratsPotential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany StudyElevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.Impact of FGF23 level on calcium and phosphorus levels in post-renal transplantation.FGF-23 in bone biology.Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically activeFibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysisFibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)FGF23 protein expression in coronary arteries is associated with impaired kidney function.Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney diseaseThe phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.Fibroblast growth factor-23 and cardiac structure and function.The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.Tumor-induced osteomalacia.Pharmacology, efficacy and safety of oral phosphate binders.Fibroblast growth factor 23 in acute kidney injury.Value of the new bone classification system in pediatric renal osteodystrophy.Chronic kidney disease: mineral and bone disorder in children.Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseCardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs.
P2860
Q24642788-891C3D3E-0D80-410D-A372-710FA747B1B3Q24653541-87182310-6B6E-46D2-BB9C-CDF19310B8A6Q26827280-D4BECC1E-99A2-465D-B734-DECDC1239DB5Q26829294-6A44AC71-6750-4092-929C-B2496B8DB918Q26852624-451D3736-DC16-4703-9550-4399EC357E60Q26860470-AC3AF896-FC2C-4264-9F3E-9BE74C189F70Q26864102-511F8E92-CA59-468D-8176-7CF3FD67FD20Q26866263-291423A6-2BAE-431B-B0FF-C709D215003CQ27000415-C4B55037-1B49-4746-9143-41892D88B5F5Q27010789-4B2D603A-E05E-4CC0-8788-4F197FB76E89Q27687570-FADCBEE0-87E3-453D-B146-09C3BD61EF8BQ28087304-43A891ED-CFA8-4B07-AEEF-FF64238D2CC6Q28507303-30362046-85BB-4032-9085-5354D60D541AQ28579798-1B90A063-043F-4E91-9DB7-6064328CDCD9Q28583506-5AEEF5BD-8828-4EA8-A884-2CA137D0A34AQ30316351-A2AC0A16-CAEB-4954-816F-7764AA17AFDBQ30427104-31B9CB1D-32F3-4234-B3E9-B3485A65D1E6Q33591785-7301F82C-EB0B-4D6B-951F-931FEC70C2B4Q33652345-493B5F95-4103-4EC1-A14E-20A9A7C34EDAQ33684986-7F512F46-7DB7-44FB-BD96-B01AE101AB1BQ33736093-926C45D0-24F2-460A-8BFB-E04910E94019Q33897866-3E9EC035-FEDC-44DA-8287-097E091C6BDCQ33932297-D7A09B6E-CACE-4A86-905C-8E43E245B20BQ33940724-80182CFD-FEF6-4C08-875B-793574FDE6E4Q33974636-F0C34B2E-4551-446C-AAA9-DE3C88E584F2Q33984825-5FD0A30F-88C9-4C31-B698-1802BE24B05FQ33985430-734BBFBA-DB41-443A-BEC5-8DB0644F9ADCQ34025119-92A9BDA4-3B21-4DF2-A187-CA9C5DECBFBFQ34027561-E39F18A5-68E8-494D-BCDA-894056AF8481Q34035797-9C8A024A-64D1-45A5-BE68-8371189A1E0AQ34039877-36CCFAC2-F9BC-4E80-935C-E9F10011D71AQ34059805-A5188F6B-6EB8-41A5-A601-3631D316A944Q34130840-1143098A-436E-4834-9178-AFFC1EAD7FA9Q34178089-AFC016B4-A13D-4BDC-B494-BD123B4DEF92Q34213752-D814C852-E1DE-441C-8363-333503895091Q34280125-D138379A-4DD9-4107-95A2-DC0CFD125BB8Q34281410-029B43F8-59C0-4163-8CC6-CA7A0AEFCB76Q34402661-6647EB60-5E5B-4962-AE60-D391426918A6Q34421217-0245ECC6-BE37-4537-ACC2-0C9440FE47A7Q34453236-2672BC68-5C9E-41BE-BD4F-C3C1A07AE3A4
P2860
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Circulating concentration of F ...... intake in healthy volunteers.
@ast
Circulating concentration of F ...... intake in healthy volunteers.
@en
type
label
Circulating concentration of F ...... intake in healthy volunteers.
@ast
Circulating concentration of F ...... intake in healthy volunteers.
@en
prefLabel
Circulating concentration of F ...... intake in healthy volunteers.
@ast
Circulating concentration of F ...... intake in healthy volunteers.
@en
P2093
P1433
P1476
Circulating concentration of F ...... intake in healthy volunteers.
@en
P2093
Harald Jüppner
Kenneth B Jonsson
Osten Ljunggren
Tobias Larsson
Ulf Nisbeth
P304
P356
10.1046/J.1523-1755.2003.00328.X
P407
P577
2003-12-01T00:00:00Z
P5875
P6179
1040393191